E22.2 Syndrome of inappropriate secretion of antidiuretic hormone

Name of the Condition

• Syndrome of Inappropriate Secretion of Antidiuretic Hormone (ICD-10 Code: E22.2)

Summary

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is characterized by excessive release of antidiuretic hormone (ADH), leading to water retention, hyponatremia, and diluted serum osmolality. This disrupts fluid balance and can cause neurological symptoms due to low sodium levels. The condition may be asymptomatic or present with mild to severe manifestations depending on the degree of hyponatremia.

Causes

SIADH is most commonly caused by ectopic ADH production, often from small cell lung carcinoma or other malignancies. Other causes include central nervous system disorders (e.g., stroke, infection), pulmonary diseases (e.g., pneumonia, tuberculosis), medications (e.g., SSRIs, carbamazepine), and postoperative states. In some cases, the cause remains idiopathic.

Risk Factors

• Malignancies, particularly small cell lung cancer.
• Central nervous system or pulmonary diseases.
• Use of medications that stimulate ADH release.
• Older age or postoperative recovery.
• Certain infections or trauma.

Symptoms

• Nausea, headache, or confusion.
• Fatigue, muscle cramps, or weakness.
• Seizures or altered mental status (in severe cases).
• Reduced urine output or concentrated urine.
• Weight gain from fluid retention.

Diagnosis

Diagnosis involves measuring serum sodium, osmolality, and ADH levels. Urine osmolality is typically inappropriately high relative to serum osmolality. Exclusion of other causes of hyponatremia (e.g., heart failure, kidney disease) is essential. Imaging or further testing may be performed to identify underlying conditions.

Treatment Options

• Fluid restriction: Limiting water intake to reduce hyponatremia.
• Medications: Vasopressin receptor antagonists (e.g., tolvaptan) to increase water excretion.
• Addressing underlying causes: Treating malignancies, infections, or discontinuing offending drugs.
• Electrolyte management: Gradual sodium correction to avoid osmotic demyelination syndrome.

Prognosis and Follow-Up

Prognosis depends on the underlying cause and severity of hyponatremia. Mild cases may resolve with fluid restriction, while severe or chronic cases require ongoing management. Regular monitoring of serum sodium and electrolytes is necessary, especially during treatment adjustments. Follow-up ensures resolution of hyponatremia and addresses any recurrence.

Complications

• Severe hyponatremia leading to seizures, coma, or death.
• Osmotic demyelination syndrome from rapid sodium correction.
• Neurological damage from prolonged low sodium levels.
• Worsening of underlying conditions (e.g., cancer progression).

Lifestyle & Prevention

• Monitor fluid intake, especially in high-risk individuals.
• Avoid excessive water consumption in susceptible populations.
• Manage underlying conditions (e.g., cancer, infections) promptly.
• Review medications with a healthcare provider to identify ADH-stimulating drugs.

When to Seek Professional Help

Seek immediate medical attention for symptoms like confusion, seizures, or severe headache, as these may indicate dangerous hyponatremia. Regular check-ups are recommended for those with risk factors or known underlying causes to monitor for SIADH development.

Tips for Medical Coders

Document the underlying cause (e.g., malignancy, medication) when coding SIADH, as it impacts clinical management and billing. Ensure lab results (serum/urine osmolality, sodium) and clinical signs are clearly recorded to support the diagnosis. Verify that other causes of hyponatremia are excluded to confirm SIADH.